Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Cyclocreatine Suppresses Creatine Metabolism and Impairs Prostate Cancer Progression.

Cancer research | 2022

Prostate cancer is the second most common cause of cancer mortality in men worldwide. Applying a novel genetically engineered mouse model (GEMM) of aggressive prostate cancer driven by deficiency of the tumor suppressors PTEN and Sprouty2 (SPRY2), we identified enhanced creatine metabolism as a central component of progressive disease. Creatine treatment was associated with enhanced cellular basal respiration in vitro and increased tumor cell proliferation in vivo. Stable isotope tracing revealed that intracellular levels of creatine in prostate cancer cells are predominantly dictated by exogenous availability rather than by de novo synthesis from arginine. Genetic silencing of creatine transporter SLC6A8 depleted intracellular creatine levels and reduced the colony-forming capacity of human prostate cancer cells. Accordingly, in vitro treatment of prostate cancer cells with cyclocreatine, a creatine analog, dramatically reduced intracellular levels of creatine and its derivatives phosphocreatine and creatinine and suppressed proliferation. Supplementation with cyclocreatine impaired cancer progression in the PTEN- and SPRY2-deficient prostate cancer GEMMs and in a xenograft liver metastasis model. Collectively, these results identify a metabolic vulnerability in prostate cancer and demonstrate a rational therapeutic strategy to exploit this vulnerability to impede tumor progression.

Pubmed ID: 35675421 RIS Download

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: Cancer Research UK, United Kingdom
    Id: A17196
  • Agency: Cancer Research UK, United Kingdom
    Id: A15151
  • Agency: Cancer Research UK, United Kingdom
    Id: A21139
  • Agency: Cancer Research UK, United Kingdom
    Id: A25045
  • Agency: Cancer Research UK, United Kingdom
    Id: A17196
  • Agency: Cancer Research UK, United Kingdom
    Id: A31287

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Thermo Xcalibur (tool)

RRID:SCR_014593

A software which acquires and processes data sets, primarily through the Xcalibur system.

View all literature mentions

PC-3M (tool)

RRID:CVCL_9555

Cell line PC-3M is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

Crl:CD1(ICR) (tool)

RRID:IMSR_CRL:022

Mus musculus with name Crl:CD1(ICR) from IMSR.

View all literature mentions

Pten+/- Ctnnb1 ex3del CP1 (cell line)

RRID:CVCL_VQ84

Cell line Pten+/- Ctnnb1 ex3del CP1 is a Cancer cell line with a species of origin Mus musculus (Mouse)

View all literature mentions

Pten-/- P1 (cell line)

RRID:CVCL_VQ82

Cell line Pten-/- P1 is a Cancer cell line with a species of origin Mus musculus (Mouse)

View all literature mentions